Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**


AGORACOM Welcomes Back Grizzly Discoveries (GZD: TSX-V)

World class gold and base metal deposits in British Columbia; and diamonds in Alberta $GZD.ca

  • More than 9 million oz Au produced or as resources in a radius of less than 70KM to Greenwood project
  • Holds, or has an interest in, metallic and industrial mineral permits for potash totaling more than 364,000 acres along the Alberta-Saskatchewan border
  • Drillholes with up to 31.1% K2O from assays on recent drill program
  • Portions of Greenwood Project being explored by Kinross through option agreement


Hub On AGORACOM / Learn More!



Namaste Announces Signing of MOU With Marijuana.Ca

  • Entered MOU with Marijuana.Ca, operator of www.marijuana.ca
  • Signing of MOU represents further achievement of the Company’s objective to increase site traffic and develop customer data in the Canadian market
  • Also coincides with the upcoming launch of www.everyonedoesit.ca, which the Company will use to further expand its position in the Canadian market



Hub On AGORACOM / Read Release


Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis

  • Announces launch of its Double-Blind Phase I Study
  • Purpose to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

Tbp large

Hub On AGORACOM / Read Release

Message: Q1 events list updated

One of the Q1 events is a Keystone Symposia (see event details below). Keystone Symposia are GREAT scientific meetings. Norm Wong presents on February 2nd discussing BET inhibitors in cardiovascular disease AND rheumatoid arthritis. It's been a while since we've heard from either Resverlogix or Zenith on their arthritis program. Hopefully that is a sign that the arthritis program is still alive and well.


Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics

January 29—February 2, 2017

Sheraton Seattle Hotel, Seattle, Washington, USA


Thursday February 2

Norm Wong, Resverlogix Corporation, Canada 

Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis


New Message
Please login to post a reply